MedMira Inc. (MIR.V)
CAD 0.08
(-5.88%)
CAD 0.08
(-5.88%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.65 Million CAD | -4.64% |
| 2022 | 3.82 Million CAD | -1.56% |
| 2021 | 3.89 Million CAD | 14.55% |
| 2020 | 3.39 Million CAD | 1244.88% |
| 2019 | 252.51 Thousand CAD | -16.08% |
| 2018 | 300.91 Thousand CAD | -55.33% |
| 2017 | 673.7 Thousand CAD | -22.55% |
| 2016 | 869.9 Thousand CAD | -51.23% |
| 2015 | 1.78 Million CAD | -3.16% |
| 2014 | 1.84 Million CAD | 57.86% |
| 2013 | 1.16 Million CAD | -60.72% |
| 2012 | 2.97 Million CAD | 99.06% |
| 2011 | 1.49 Million CAD | 162.62% |
| 2010 | 568.17 Thousand CAD | 8.55% |
| 2009 | 523.41 Thousand CAD | -37.18% |
| 2008 | 833.18 Thousand CAD | -70.91% |
| 2007 | 2.86 Million CAD | -28.54% |
| 2006 | 4 Million CAD | 180.64% |
| 2005 | 1.42 Million CAD | -15.67% |
| 2004 | 1.69 Million CAD | -28.26% |
| 2003 | 2.36 Million CAD | -29.8% |
| 2002 | 3.36 Million CAD | 11.05% |
| 2001 | 3.02 Million CAD | -16.26% |
| 2000 | 3.61 Million CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 4.46 Million CAD | -2.63% |
| 2024 Q1 | 4.58 Million CAD | 25.58% |
| 2024 Q3 | 6.36 Million CAD | 42.54% |
| 2023 Q2 | 3.72 Million CAD | -1.4% |
| 2023 FY | 3.65 Million CAD | -4.64% |
| 2023 Q1 | 3.77 Million CAD | -1.38% |
| 2023 Q4 | 3.65 Million CAD | -4.62% |
| 2023 Q3 | 3.82 Million CAD | 2.81% |
| 2022 Q2 | 4.55 Million CAD | -6.47% |
| 2022 Q4 | 3.82 Million CAD | -6.55% |
| 2022 Q1 | 4.86 Million CAD | 25.15% |
| 2022 FY | 3.82 Million CAD | -1.56% |
| 2022 Q3 | 4.09 Million CAD | -10.01% |
| 2021 Q1 | 4.56 Million CAD | 34.28% |
| 2021 Q2 | 3.99 Million CAD | -12.31% |
| 2021 FY | 3.89 Million CAD | 14.55% |
| 2021 Q3 | 3.67 Million CAD | -8.01% |
| 2021 Q4 | 3.89 Million CAD | 5.75% |
| 2020 Q1 | 2.66 Million CAD | 955.27% |
| 2020 Q2 | 2.83 Million CAD | 6.29% |
| 2020 Q3 | 3.09 Million CAD | 9.4% |
| 2020 Q4 | 3.39 Million CAD | 9.61% |
| 2020 FY | 3.39 Million CAD | 1244.88% |
| 2019 FY | 252.51 Thousand CAD | -16.08% |
| 2019 Q4 | 252.51 Thousand CAD | -8.27% |
| 2019 Q3 | 275.28 Thousand CAD | -14.97% |
| 2019 Q2 | 323.75 Thousand CAD | 11.87% |
| 2019 Q1 | 289.4 Thousand CAD | -3.82% |
| 2018 Q4 | 300.91 Thousand CAD | 8.48% |
| 2018 FY | 300.91 Thousand CAD | -55.33% |
| 2018 Q1 | 619.21 Thousand CAD | -8.09% |
| 2018 Q2 | 348.03 Thousand CAD | -43.79% |
| 2018 Q3 | 277.39 Thousand CAD | -20.3% |
| 2017 Q4 | 673.7 Thousand CAD | -3.55% |
| 2017 Q2 | 816.32 Thousand CAD | -5.44% |
| 2017 Q1 | 863.24 Thousand CAD | -0.77% |
| 2017 Q3 | 698.53 Thousand CAD | -14.43% |
| 2017 FY | 673.7 Thousand CAD | -22.55% |
| 2016 Q4 | 869.9 Thousand CAD | -59.49% |
| 2016 FY | 869.9 Thousand CAD | -51.23% |
| 2016 Q3 | 2.14 Million CAD | -44.8% |
| 2016 Q2 | 3.88 Million CAD | -17.62% |
| 2016 Q1 | 4.72 Million CAD | 164.71% |
| 2015 FY | 1.78 Million CAD | -3.16% |
| 2015 Q3 | 1.28 Million CAD | 3.52% |
| 2015 Q4 | 1.78 Million CAD | 39.14% |
| 2015 Q1 | 1.68 Million CAD | -8.4% |
| 2015 Q2 | 1.23 Million CAD | -26.61% |
| 2014 Q4 | 1.84 Million CAD | 3.26% |
| 2014 Q1 | 5.72 Million CAD | 390.91% |
| 2014 FY | 1.84 Million CAD | 57.86% |
| 2014 Q2 | 3.59 Million CAD | -37.26% |
| 2014 Q3 | 1.78 Million CAD | -50.37% |
| 2013 Q3 | 858.38 Thousand CAD | -32.58% |
| 2013 Q1 | 2.19 Million CAD | -25.96% |
| 2013 FY | 1.16 Million CAD | -60.72% |
| 2013 Q4 | 1.16 Million CAD | 35.93% |
| 2013 Q2 | 1.27 Million CAD | -42.11% |
| 2012 Q1 | 517.98 Thousand CAD | -65.29% |
| 2012 Q3 | 591.05 Thousand CAD | -0.1% |
| 2012 FY | 2.97 Million CAD | 99.06% |
| 2012 Q4 | 2.97 Million CAD | 402.53% |
| 2012 Q2 | 591.66 Thousand CAD | 14.22% |
| 2011 Q2 | 570.18 Thousand CAD | -7.49% |
| 2011 Q1 | 616.38 Thousand CAD | 8.48% |
| 2011 Q3 | 517.96 Thousand CAD | -9.16% |
| 2011 Q4 | 1.49 Million CAD | 188.08% |
| 2011 FY | 1.49 Million CAD | 162.62% |
| 2010 FY | 568.17 Thousand CAD | 8.55% |
| 2010 Q1 | 490.64 Thousand CAD | -6.26% |
| 2010 Q2 | 1.2 Million CAD | 146.14% |
| 2010 Q3 | 1.03 Million CAD | -14.52% |
| 2010 Q4 | 568.17 Thousand CAD | -44.96% |
| 2009 Q1 | 822.25 Thousand CAD | -1.31% |
| 2009 Q2 | 764.14 Thousand CAD | -7.07% |
| 2009 Q3 | 690.82 Thousand CAD | -9.59% |
| 2009 Q4 | 523.41 Thousand CAD | -24.23% |
| 2009 FY | 523.41 Thousand CAD | -37.18% |
| 2008 Q1 | 2.54 Million CAD | -11.27% |
| 2008 FY | 833.18 Thousand CAD | -70.91% |
| 2008 Q4 | 833.18 Thousand CAD | -67.34% |
| 2008 Q3 | 2.55 Million CAD | -11.12% |
| 2008 Q2 | 2.86 Million CAD | 12.93% |
| 2007 FY | 2.86 Million CAD | -28.54% |
| 2007 Q1 | 3.79 Million CAD | -5.28% |
| 2007 Q3 | 3.72 Million CAD | -10.33% |
| 2007 Q4 | 2.86 Million CAD | -23.12% |
| 2007 Q2 | 4.15 Million CAD | 9.43% |
| 2006 FY | 4 Million CAD | 180.64% |
| 2006 Q4 | 4 Million CAD | -4.86% |
| 2006 Q3 | 4.21 Million CAD | 113.47% |
| 2006 Q1 | 1.73 Million CAD | 21.31% |
| 2006 Q2 | 1.97 Million CAD | 13.91% |
| 2005 Q4 | 1.42 Million CAD | -11.66% |
| 2005 FY | 1.42 Million CAD | -15.67% |
| 2005 Q1 | 1.61 Million CAD | -4.42% |
| 2005 Q2 | 1.43 Million CAD | -11.53% |
| 2005 Q3 | 1.61 Million CAD | 12.89% |
| 2004 Q1 | 1.59 Million CAD | -32.6% |
| 2004 FY | 1.69 Million CAD | -28.26% |
| 2004 Q3 | 1.59 Million CAD | 3.42% |
| 2004 Q4 | 1.69 Million CAD | 6.02% |
| 2004 Q2 | 1.54 Million CAD | -2.92% |
| 2003 Q3 | 1.49 Million CAD | -25.71% |
| 2003 Q1 | 2.39 Million CAD | -28.89% |
| 2003 FY | 2.36 Million CAD | -29.8% |
| 2003 Q2 | 2 Million CAD | -15.97% |
| 2003 Q4 | 2.36 Million CAD | 58.14% |
| 2002 Q3 | 2.68 Million CAD | -2.68% |
| 2002 FY | 3.36 Million CAD | 11.05% |
| 2002 Q2 | 2.75 Million CAD | -1.74% |
| 2002 Q4 | 3.36 Million CAD | 25.35% |
| 2002 Q1 | 2.8 Million CAD | 0.0% |
| 2001 FY | 3.02 Million CAD | -16.26% |
| 2000 FY | 3.61 Million CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Arch Biopartners Inc. | 1.17 Million CAD | -211.807% |
| Covalon Technologies Ltd. | 24.9 Million CAD | 85.334% |
| Hemostemix Inc. | 313.76 Thousand CAD | -1063.865% |
| Universal Ibogaine Inc. | 6.31 Million CAD | 42.197% |
| Kane Biotech Inc. | 5.68 Million CAD | 35.718% |
| Marvel Biosciences Corp. | 672.38 Thousand CAD | -443.109% |
| NervGen Pharma Corp. | 13.23 Million CAD | 72.41% |
| XORTX Therapeutics Inc. | 7.21 Million CAD | 49.351% |